Resurgent Financial Advisors’s Gilead Sciences GILD Stock Holding History

Resurgent Financial Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,407	Closed	-$195K	–	297
2023 Q4	$195K	Buy	2,407 +263	+12%	+$20.5K	0.12%	169
2023 Q3	$161K	Buy	2,144 +79	+4%	+$6.08K	0.11%	169
2023 Q2	$159K	Sell	2,065 -48	-2%	-$3.83K	0.11%	174
2023 Q1	$175K	Sell	2,113 -2,115	-50%	-$175K	0.12%	163
2022 Q4	$363K	Sell	4,228 -235	-5%	-$18.6K	0.19%	122
2022 Q3	$276K	Buy	4,463 +1,149	+35%	+$72.5K	0.18%	143
2022 Q2	$205K	Sell	3,314 -1,559	-32%	-$96.5K	0.13%	175
2022 Q1	$289K	Buy	+4,873	New	+$311K	0.18%	133

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Resurgent Financial Advisors's GILD Position: Q1 2024 in Review

Resurgent Financial Advisors sold out of Gilead Sciences (GILD) in Q1 2024, closing a stake of 2,407 shares — an estimated $195K sold.

Resurgent Financial Advisors first reported a position in GILD in Q1 2022 and held it in 8 quarters. The position peaked at $363K in Q4 2022. 1,721 funds tracked by Wall St. Rank hold GILD as of Q1 2024.

Resurgent Financial Advisors reported no remaining Gilead Sciences position as of Q1 2024 after selling out during the quarter.
Resurgent Financial Advisors sold 2,407 Gilead Sciences shares in Q1 2024, an estimated $195K.
Resurgent Financial Advisors first reported a position in Gilead Sciences in Q1 2022 and held it in 8 quarters.
Resurgent Financial Advisors's Gilead Sciences position peaked at $363K in Q4 2022.
1,721 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2024.

Based on Resurgent Financial Advisors's 13F filing for Q1 2024, filed 10 May 2024.